A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Paused · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor, Gynecologic Cancer

In brief

This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed state (Food Effect)

Key facts

Study ID
NCT04042116
Run by
Clovis Oncology, Inc.
People needed
227
Starts
2019-07-29
Expected to finish
2024-01-01
Last updated by the study team
2022-12-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.